Mr. Donald McCaffrey reports
RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
Resverlogix Corp. has held its annual meeting of shareholders in Calgary, Alta.
During business proceedings at the meeting, shareholders elected five board members until the next annual meeting. The voting results of shares represented at the meeting for individual directors are set out in the attached table.
VOTING RESULTS FOR ELECTION OF DIRECTORS
Votes for Votes withheld Per cent for Per cent withheld
Donald J. McCaffrey 125,007,142 7,326,179 94.46% 5.54%
Shawn Lu 126,119,539 6,213,782 95.30% 4.70%
Kelly McNeill 125,955,508 6,377,813 95.18% 4.82%
Siu Lun (Dicky) To 127,354,197 4,979,124 96.24% 3.76%
Kenneth Zuerblis 127,166,543 5,166,778 96.10% 3.90%
Resverlogix shareholders approved all resolutions outlined in the notice of meeting and management information circular dated May 11, 2022. The information circular is available on SEDAR and on the Resverlogix website.
A webcast archive of the executive presentation portion of the meeting will be available.
About Resverlogix Corp.
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. It aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.
The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated co-morbidities and COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange (RVX).
© 2023 Canjex Publishing Ltd. All rights reserved.